M-83 Drugs and treatments for rare diseases
43rd Parliament, 2nd Session
Motion Text
That, in the opinion of the House, given the fact that access to drug and treatment for Canadians with rare diseases is an ongoing issue, the government should:
(i) work to reduce the approval process for its Priority Review of drug submissions, which is currently set at 180 days,
(ii) ask the Canadian Agency for Drug and Technologies in Health, the Patented Medicine Prices Review Board, and the pan-Canadian Pharmaceutical Alliance to draft a strategy to expedite the approval of drugs that deal with terminal rare diseases,
(iii) work with the provinces and territories to help identify current barriers to faster drug approval and accessibility.
(i) work to reduce the approval process for its Priority Review of drug submissions, which is currently set at 180 days,
(ii) ask the Canadian Agency for Drug and Technologies in Health, the Patented Medicine Prices Review Board, and the pan-Canadian Pharmaceutical Alliance to draft a strategy to expedite the approval of drugs that deal with terminal rare diseases,
(iii) work with the provinces and territories to help identify current barriers to faster drug approval and accessibility.
Latest Activity
- Monday, May 31, 2021
- Placed in the Order of Precedence
History
- Thursday, April 29, 2021
-
Placed on Notice
- Monday, May 31, 2021
-
Placed in the Order of Precedence